NESTLÉ S.A. 2020 operating segments restated
Nestlé Health Science and Nespresso disclosed as separate reportable segments as from January 2021.
As part of our Press Release related to Nestlé Group full-year 2020 results, we announced that the two Globally Managed Businesses Nestlé Health Science and Nespresso will be reported as stand-alone reportable segments, as of 2021 onwards (previously combined and presented in Other businesses). This change reflects the increasing financial contribution of those two businesses to the Group and provides greater transparency on their respective performance.
Consequently, and in order to enable a relevant comparability in 2021, we are re-publishing the 2020 set of financial results by operating segment as follows:
▪ 2020 3M sales (Appendix 1)
▪ 2020 half-year figures (Appendix 2)
▪ 2020 9M sales (Appendix 3)
▪ 2020 full-year figures (Appendix 4)
In addition, we are also re-publishing the Organic Sales Growth (Real Internal Growth and Pricing) by operating segment, for the same periods (Appendix 5).
Nestlé Investor Relations
Three-month sales: January - March 2020
In millions of CHF
APPENDIX 1 | |
January-March | |
2020 | |
January-March | as originally |
2020 restated * | published |
Sales | Sales |
By operating segment | ||
Zone EMENA | 5 313 | 5 313 |
Zone AMS | 8 347 | 8 347 |
Zone AOA | 4 974 | 4 974 |
Nespresso | 1 359 | - |
Nestlé Health Science | 765 | - |
Other businesses (a) | 54 | 2 178 |
Total | 20 812 | 20 812 |
By product | ||
Powdered and Liquid Beverages | 5 440 | 5 440 |
Water | 1 586 | 1 586 |
Milk products and Ice cream | 2 642 | 2 642 |
Nutrition and Health Science | 3 058 | 3 058 |
Prepared dishes and cooking aids | 2 952 | 2 952 |
Confectionery | 1 632 | 1 632 |
PetCare | 3 502 | 3 502 |
Total | 20 812 | 20 812 |
* 2020 figures restated following Nestlé Health Science and Nespresso disclosed as reportable segments from 2021 onwards (previously combined and presented in Other businesses).
(a) Composed of businesses not under the direct control of the Zones or GMBs and Group procurement activities.
3. Analyses by segment for the period ended June 30, 2020 | |||
3.1 Operating segments | |||
Revenue and results | |||
In millions of CHF | |||
(76) | (18) | (51) | (425) |
(21) | (10) | 1 | (616) |
(48) | (28) | (18) | (355) |
3 | 1 | 1 | (167) |
(2) | - | (1) | (67) |
(1) | - | 1 | (20) |
(41) | (19) | 1 | (58) |
(186) | (74) | (66) | (1 708) |
In millions of CHF | |||
January-June | |||
2020 | |||
as originally | |||
published | |||
(76) | (18) | (51) | (425) |
(21) | (10) | 1 | (616) |
(48) | (28) | (18) | (355) |
- | 1 | 1 | (254) |
(41) | (19) | 1 | (58) |
(186) | (74) | (66) | (1 708) |
January-June 2020 restated *
Zone EMENA Zone AMS Zone AOA
Other businesses Unallocated items (e) Total
Sales (a)UnderlyingTrading operating profit (b)
Trading operatingprofit
Zone EMENA | 10 029 1 840 1 764 |
Zone AMS | 16 674 3 150 3 129 |
Zone AOA | 10 062 2 282 2 234 |
Nespresso | 2 762 714 717 |
Nestlé Health Science | 1 540 297 295 |
Other businesses (d) | 85 (24) (25) |
Unallocated items (e) | - (1 103) (1 144) |
Total | 41 152 7 156 6 970 |
Sales (a)UnderlyingTrading operating profit (b)
Trading operatingprofit
10 029
1 840
1 764
16 674
3 150
3 129
10 062
2 282
2 234
4 387 - 41 152
976
976
(1 092)
(1 133)
7 156
6 970
Netothertrading income/(expenses) (c)
of which impairment of property, plant and equipment
of which restructuringcosts
Netothertrading income/(expenses) (c)
of which impairment of property, plant and equipment
of which restructuringcosts
Depreciation andamortisation
Depreciation andamortisation
* 2020 figures restated following Nestlé Health Science and Nespresso disclosed as reportable segments from 2021 onwards (previously combined and presented in Other businesses).
(a) Inter-segment sales are not significant.
(b) Trading operating profit before Net other trading income/(expenses).
(c) Included in Trading operating profit.
(d) Composed of businesses not under the direct control of the Zones or GMBs and Group procurement activities.
(e) Mainly corporate expenses as well as research and development costs.
3. Analyses by segment for the period ended June 30, 2020 (continued)
3.1 Operating segments (continued)
Other information
In millions of CHF
January-June 2020 restated *
Impairmentof goodwilland non-commercialized intangibleassets(c)
Impairmentof intangibleassets(d)
Zone EMENA | - - |
Zone AMS | (30) - |
Zone AOA | - - |
Nespresso | - - |
Nestlé Health Science | (6) - |
Other businesses (a) | (383) - |
Unallocated items (b) | - - |
Total | (419) - |
In millions of CHF
January-June 2020 as originally published
Impairmentof goodwilland non-commercialized intangibleassets(c)
Impairmentof intangibleassets(d)
Zone EMENA Zone AMS Zone AOA
Other businesses Unallocated items (b) Total
(419)
(389)
(30)
-
-
-
- - - - - -
* 2020 figures restated following Nestlé Health Science and Nespresso disclosed as reportable segments from 2021 onwards (previously combined and presented in Other businesses).
(a) Composed of businesses not under the direct control of the Zones or GMBs and Group procurement activities.
(b) Mainly corporate and research and development assets.
(c) Included in Operating profit.
(d) Included in Trading operating profit.
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Nestlé SA published this content on 25 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 March 2021 17:10:03 UTC.
